Chronic mirabegron treatment increases human brown fat, HDL cholesterol, and insulin sensitivity

BACKGROUND: Mirabegron is a β3-adrenergic receptor (β3-AR) agonist approved only for the treatment of overactive bladder. Encouraging preclinical results suggest that β3-AR agonists could also improve obesity-related metabolic disease by increasing brown adipose tissue (BAT) thermogenesis, white adi...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:J Clin Invest
Autores principales: O’Mara, Alana E., Johnson, James W., Linderman, Joyce D., Brychta, Robert J., McGehee, Suzanne, Fletcher, Laura A., Fink, Yael A., Kapuria, Devika, Cassimatis, Thomas M., Kelsey, Nathan, Cero, Cheryl, Sater, Zahraa Abdul, Piccinini, Francesca, Baskin, Alison S., Leitner, Brooks P., Cai, Hongyi, Millo, Corina M., Dieckmann, William, Walter, Mary, Javitt, Norman B., Rotman, Yaron, Walter, Peter J., Ader, Marilyn, Bergman, Richard N., Herscovitch, Peter, Chen, Kong Y., Cypess, Aaron M.
Formato: Artigo
Lenguaje:Inglês
Publicado: American Society for Clinical Investigation 2020
Materias:
Clinical Medicine
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC7190915/
https://ncbi.nlm.nih.gov/pubmed/31961826
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1172/JCI131126
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares